Agoracom Blog

Tetra Bio-Pharma Appoints Aphria CFO, Mr. Carl Merton to the Board of Directors $TBP.ca

Posted by AGORACOM-JC at 9:00 AM on Wednesday, June 14th, 2017

https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564502/hub/TBP_large.jpg

  • Appointed Mr. Carl A. Merton to the Board of Directors, effective immediately. 

OTTAWA, ONTARIO–(June 14, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN)(CNSX:TBP)(OTCQB:TBPMF) today announced that it has appointed Mr. Carl A. Merton to the Board of Directors, effective immediately.

Mr. Merton has over 20 years of financial and business experience, including 10 years experience as a CFO for public companies involved in the capital markets. Beginning with 12 years combined with Ernst & Young and KPMG, he transitioned from the audit stream into financial advisory work, as a Business Valuator, Forensic Accountant and Corporate Finance functions. After leaving KPMG, Mr. Merton joined Atlas Tube Inc., as Vice-President, Special Projects. After assisting in the sale of Atlas Tube, Mr. Merton became the CFO of Reko International Group Inc. In December 2014, Mr. Merton was elected by shareholders as a member of the inaugural Board of Directors of Aphria Inc. Approximately one year later, Mr. Merton resigned as a member of the Board and joined Aphria as its CFO. In his role as CFO, Mr. Merton is responsible for communication with all stakeholders and is a member of the executive management team responsible for the strategic direction of Aphria, as well as leading all acquisition discussions, budgeting, financing, financial reporting and internal controls. Mr. Merton is a Chartered Professional Accountant, a Chartered Accountant and is a Fellow of the Canadian Institute of Chartered Business Valuators (the “CICBV”). He holds a B.Comm. Hon. in Sports Administration from Laurentian University, and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.

“We are most pleased to welcome Mr. Merton to the board as we continue to work closely with our strategic partner, Aphria in building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, Chairman and CEO of Tetra Bio-Pharma. “Mr. Merton’s tremendous experience as a CFO of publicly listed companies has resulted in raising in excess of $200 million. His vast network both in the U.S. and Canada will be a key factor in the Company’s growth. We look forward to working closely with him in building Tetra as a global leader in pharmaceutical cannabis.”

About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(OTCQB:TBPMF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.

Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.

Source: Tetra Bio-Pharma

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(514) 360-8040 Ext. 20

Tags: , ,

Comments are closed.